Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy

Overview of attention for article published in Clinical Ophthalmology, February 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 3,214 followers.

#Rituximab as a monotherapy or combination therapy for the treatment of non-paraneoplastic autoimmune #retinopathy https://t.co/g0rvlkUB3b

RT @uveitis1: .#Rituximab as monotherapy or in combination therapy for treatment of non-paraneoplastic autoimmune #retinopathy https://t.co…

RT @uveitis1: .#Rituximab as monotherapy or in combination therapy for treatment of non-paraneoplastic autoimmune #retinopathy https://t.co…

.#Rituximab as monotherapy or in combination therapy for treatment of non-paraneoplastic autoimmune #retinopathy https://t.co/VyHaZElRpd